Anne S.Tsao, MD, and Edward B. Garon, MD, MS, review clinical trial data and discuss the evolving role of antibody-drug conjugates and TROP2-directed therapies in the treatment of patients with non–small cell lung cancer.
EP. 1: Overview of Non–Small Cell Lung Cancer
Anne S. Tsao, MD, and Edward B. Garon, MD, MS, introduce themselves and provide an overview of the incidence, prognosis, and treatment of non–small cell lung cancer.
EP. 2: The Role of Biomarkers in NSCLC Treatment
Thoracic medical oncologists discuss the evolving role of biomarkers in the non–small cell lung cancer treatment landscape.
EP. 3: NSCLC Treatment: Unmet Needs and Antibody-Drug Conjugates
Expert perspectives on unmet needs in the NSCLC treatment landscape and the role of antibody-drug conjugates in addressing them.
EP. 4: The Role of TROP2 as a Biomarker in NSCLC
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, provide an overview of TROP2 as a target for patients with non–small cell lung cancer.
EP. 5: NSCLC: Preclinical Studies on TROP2 Expression
A review of preclinical studies looking at TROP2 expression in patients with non–small cell lung cancer.
EP. 6: Lung Cancer Treatment: Antibody-Drug Conjugates
Experts on non–small cell lung cancer discuss the role of antibody-drug conjugates and review their mechanism of action.
EP. 7: Clinical Trial Data on Sacituzumab Govitecan in NSCLC
Comprehensive insights on clinical trial data that have led to further development of sacituzumab govitecan for patients with non–small cell lung cancer.
EP. 8: EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in First-Line Metastatic NSCLC
Thoracic oncologists discuss the EVOKE-02 study investigating sacituzumab govitecan in combination with pembrolizumab in patients with first-line metastatic NSCLC.
2 Clarke Drive Cranbury, NJ 08512